AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36897521 — intervention group
Group type: COMPARATOR
Intervention: Individual formulations (Ezetimibe and Rosuvastatin)
Number of subjects: 68
Study 33665879 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative wealth shock
Number of subjects: 0
Study 33665879 — intervention group
Group type: COMPARATOR
Intervention: Marginal structural models (MSM)
Number of subjects: 0
Study 33665879 — intervention group
Group type: COMPARATOR
Intervention: Principal stratification (PS)
Number of subjects: 0
Study 33800281 — intervention group
Group type: EXPERIMENTAL
Intervention: Long‐term Innovative Follow‐up Extension (LIFE) component
Number of subjects: 140
Study 33800281 — intervention group
Group type: EXPERIMENTAL
Intervention: REB approval process
Number of subjects: 140
Study 33285100 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminaria
Number of subjects: 67
Study 33285100 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 67
Study 32414405 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced quarterly counseling on HIV risk reduction, couple communication, family planning and nutrition delivered by study counselors through up to 24 months postpartum
Number of subjects: 1230
Study 32414405 — intervention group
Group type: COMPARATOR
Intervention: Standard post-test counseling
Number of subjects: 1230
Study 33549133 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic natural orifice specimen extraction surgery (NOSES)
Number of subjects: 550
Study 33549133 — intervention group
Group type: COMPARATOR
Intervention: Traditional robotic-assisted surgery
Number of subjects: 550
Study 33477143 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care ultrasonography (POCUS)
Number of subjects: 0
Study 33477143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinational ultrasound evaluation
Number of subjects: 0
Study 32248857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (8-week duration, incorporated into the standard falls prevention class)
Number of subjects: 22
Study 32248857 — intervention group
Group type: COMPARATOR
Intervention: Standard falls prevention class (control group)
Number of subjects: 22
Study 36223865 — intervention group
Group type: EXPERIMENTAL
Intervention: Health red-meat-reduction message
Number of subjects: 2773
Study 36223865 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental red-meat-reduction message
Number of subjects: 2773
Study 36223865 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal welfare red-meat-reduction message
Number of subjects: 2773
Study 36223865 — intervention group
Group type: COMPARATOR
Intervention: Control message (neutral, non-red meat message)
Number of subjects: 2773
Study 35655482 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Hz binaural beats
Number of subjects: 31
Study 35655482 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term training
Number of subjects: 31
Study 35655482 — intervention group
Group type: EXPERIMENTAL
Intervention: Aging and reduced sound intervention volume
Number of subjects: 31
Study 32301407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry beverage (450 ml daily for 8 weeks)
Number of subjects: 35
Study 32301407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry beverage
Number of subjects: 35
Study 32301407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 35708621 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class nutrition education with in-class feeding content
Number of subjects: 382
Study 35708621 — intervention group
Group type: EXPERIMENTAL
Intervention: In-class nutrition education with online feeding content
Number of subjects: 382
Study 35708621 — intervention group
Group type: COMPARATOR
Intervention: In-class nutrition education only
Number of subjects: 382
Study 33419890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 346
Study 33419890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 346
Study 32387531 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with calorie information presented relative to the highest calorie item
Number of subjects: 633
Study 32387531 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with calorie information presented relative to the lowest calorie item
Number of subjects: 633
Study 32387531 — intervention group
Group type: COMPARATOR
Intervention: Condition with per-item calorie information
Number of subjects: 633
Study 32387531 — intervention group
Group type: COMPARATOR
Intervention: No calorie information (control condition)
Number of subjects: 633
Study 35124320 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus endocrine therapy (ET)
Number of subjects: 178
Study 35124320 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 178
Study 33221186 — intervention group
Group type: COMPARATOR
Intervention: Violence Prevention Program (VPP)
Number of subjects: 100
Study 33221186 — intervention group
Group type: COMPARATOR
Intervention: Positive Youth Development Program (PYDP)
Number of subjects: 100
Study 32049861 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine double-balloon catheter
Number of subjects: 224
Study 32049861 — intervention group
Group type: COMPARATOR
Intervention: Gauze packing
Number of subjects: 224
Study 35206481 — intervention group
Group type: EXPERIMENTAL
Intervention: Yes VR group (VR analgesia)
Number of subjects: 82
Study 35206481 — intervention group
Group type: COMPARATOR
Intervention: No VR group (non‐medical conversation)
Number of subjects: 82
Study 34384855 — intervention group
Group type: COMPARATOR
Intervention: Expiration Breath Hold (EBH)
Number of subjects: 18
Study 34384855 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath Hold (DIBH)
Number of subjects: 18
Study 34384855 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiration Breath Hold (IBH)
Number of subjects: 18
Study 34384855 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized technique
Number of subjects: 18
Study 34384855 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized technique (not EBH)
Number of subjects: 18
Study 32819350 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Aerobic Exercise Program (CAEP)
Number of subjects: 90
Study 32819350 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 90
Study 32819350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 35796392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 800 mcg/day intranasally for 12 weeks
Number of subjects: 92
Study 35796392 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 0.5 mg/kg/day orally for 7 days, followed by a decreasing dosage for another week
Number of subjects: 92
Study 35796392 — intervention group
Group type: COMPARATOR
Intervention: Systemic steroid therapy
Number of subjects: 92
Study 35796392 — intervention group
Group type: COMPARATOR
Intervention: Intranasal steroid therapy
Number of subjects: 92
Study 33466246 — intervention group
Group type: COMPARATOR
Intervention: AB Serum (ABS)
Number of subjects: 28
Study 33466246 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 28
Study 33466246 — intervention group
Group type: COMPARATOR
Intervention: Mesenchymal stromal cells (STx.)
Number of subjects: 28
Study 33466246 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells in hyaluronic acid (HA + STx.)
Number of subjects: 28
Study 36149968 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 90
Study 36149968 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 90
Study 34369698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture of Tiaoren Tongdu (applied to specific acupuncture points, needles retained for 30 min, treatment once every other day, 3 times a week for 8 weeks)
Number of subjects: 116
Study 34369698 — intervention group
Group type: COMPARATOR
Intervention: Non-acupuncture group (psychotherapy, once daily for 8 weeks)
Number of subjects: 116
Study 34369698 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture B group (less than 6 treatments)
Number of subjects: 116
Study 35101364 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab plus metronomic chemotherapy (TPM)
Number of subjects: 80
Study 35101364 — intervention group
Group type: COMPARATOR
Intervention: Pertuzumab plus trastuzumab (TP)
Number of subjects: 80
Study 34391982 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 317
Study 34391982 — intervention group
Group type: COMPARATOR
Intervention: PCEA + PIEB
Number of subjects: 317
Study 32653606 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of mifepristone every other day for two months followed by insertion of an LNG-IUS 52 mg
Number of subjects: 58
Study 32653606 — intervention group
Group type: COMPARATOR
Intervention: Comparator (not specified)
Number of subjects: 58
Study 33196290 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial phytase (0, 500, and 2000 FTU/kg)
Number of subjects: 48
Study 32930855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring curettage
Number of subjects: 347
Study 32930855 — intervention group
Group type: COMPARATOR
Intervention: 3D histologically controlled surgery
Number of subjects: 347
Study 32930855 — intervention group
Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 347
Study 36387992 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 60‐min sessions of Brief Prolonged Exposure Therapy (Brief PE)
Number of subjects: 200
Study 36387992 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 200
Study 33431162 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievable inferior vena cava filter (rIVCF)
Number of subjects: 42
Study 33431162 — intervention group
Group type: COMPARATOR
Intervention: No rIVCF (Control)
Number of subjects: 42
Study 34475499 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted IL-1Racp
Number of subjects: 0
Study 34475499 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted IL-1α
Number of subjects: 0
Study 34475499 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β, IL-1Ra, IL-36γ
Number of subjects: 0
Study 34475499 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1α/β, IL-1Ra
Number of subjects: 0
Study 34475499 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1β, IL-18BP
Number of subjects: 0
Study 32362147 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-focused (EM) writing group
Number of subjects: 71
Study 32362147 — intervention group
Group type: COMPARATOR
Intervention: Fact-focused (FC) writing group
Number of subjects: 71
Study 35410238 — intervention group
Group type: EXPERIMENTAL
Intervention: New ultrasound‐guided teaching group (acoustic shadowing‐facilitated ultrasound guidance)
Number of subjects: 116
Study 35410238 — intervention group
Group type: COMPARATOR
Intervention: Traditional ultrasound‐guided teaching group
Number of subjects: 116
Study 35410238 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 33446126 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home electronic medication dispensing system (MDS)
Number of subjects: 50
Study 33446126 — intervention group
Group type: COMPARATOR
Intervention: Current methods of medication management (Control)
Number of subjects: 50
Study 33154284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine 20 mg every 30 min up to 5 doses
Number of subjects: 78
Study 33154284 — intervention group
Group type: COMPARATOR
Intervention: Intravenous hydralazine 10 mg every 30 min up to 5 doses
Number of subjects: 78
Study 33154284 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine and intravenous hydralazine
Number of subjects: 78
Study 35400298 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 16
Study 35400298 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Ischemic Preconditioning (LIPC)
Number of subjects: 16
Study 35400298 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 33615512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment on the forearm
Number of subjects: 10
Study 33615512 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment
Number of subjects: 10
Study 32072587 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised EMA Guideline on Strategies to Identify and Mitigate Risks for First‐in‐Human and Early Clinical Trials
Number of subjects: 0
Study 32072587 — intervention group
Group type: EXPERIMENTAL
Intervention: Case studies discussed during the DIAlogue Session
Number of subjects: 0
Study 35450742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once daily
Number of subjects: 102
Study 35450742 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg per day
Number of subjects: 102
Study 35450742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined solifenacin 5 mg and mirabegron 50 mg once daily
Number of subjects: 102
Study 35450742 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 102
Study 34544853 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific motor therapy (20 extra hours) starting at ≤30 days after stroke (acute)
Number of subjects: 0
Study 34544853 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific motor therapy (20 extra hours) starting at 2 to 3 months after stroke (subacute)
Number of subjects: 0
Study 34544853 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-specific motor therapy (20 extra hours) starting at ≥6 months after stroke (chronic)
Number of subjects: 0
Study 34544853 — intervention group
Group type: COMPARATOR
Intervention: Standard motor rehabilitation (control group)
Number of subjects: 0
Study 32746668 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-mobility (DM) cup
Number of subjects: 1100
Study 32746668 — intervention group
Group type: COMPARATOR
Intervention: Unipolar (UP) cup
Number of subjects: 1100
Study 36162613 — intervention group
Group type: EXPERIMENTAL
Intervention: Bystander CPR
Number of subjects: 420671
Study 36162613 — intervention group
Group type: COMPARATOR
Intervention: No bystander CPR
Number of subjects: 420671
Study 33431304 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-dosed carbohydrate-electrolyte solution
Number of subjects: 12
Study 33431304 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte trial
Number of subjects: 12
Study 32350650 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of prismatic side-effects of spectacle lenses and eye ball length in dosage planning (intervention group)
Number of subjects: 101
Study 32350650 — intervention group
Group type: COMPARATOR
Intervention: No consideration of prismatic side-effects of spectacle lenses and eye ball length in dosage planning (control group)
Number of subjects: 101
Study 32350650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 101
Study 32350650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (esotropic patients)
Number of subjects: 101
Study 32350650 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (patients with hyperopia > + 2 D)
Number of subjects: 101
Study 35172056 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-938 600 mg once daily
Number of subjects: 178
Study 35172056 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-938 300 mg twice daily after a 500 mg loading dose
Number of subjects: 178
Study 35172056 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 35172056 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-938 300 mg once daily after a 600 mg loading dose
Number of subjects: 178
Study 35172056 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-938 200 mg twice daily after a 400 mg loading dose
Number of subjects: 178
Study 35172056 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP-938 (all regimens)
Number of subjects: 178
Study 34098518 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant (50 mg)
Number of subjects: 0
Study 34098518 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant (50 mg) + Citalopram (20 mg at steady state)
Number of subjects: 0
Study 34098518 — intervention group
Group type: COMPARATOR
Intervention: Citalopram (20 mg, single dose and at steady state)
Number of subjects: 0
Study 34098518 — intervention group
Group type: EXPERIMENTAL
Intervention: Daridorexant (50 mg) + Citalopram (20 mg)
Number of subjects: 0
Study 32921123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi exercises (24 simplified tai chi exercises)
Number of subjects: 98
Study 32921123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi exercises
Number of subjects: 98
Study 32921123 — intervention group
Group type: COMPARATOR
Intervention: Grip strength exercise (control group)
Number of subjects: 98
Study 35747613 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 75
Study 35747613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory Kinesio taping
Number of subjects: 75
Study 35747613 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study 33832947 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-nephrectomy KIM-1 levels
Number of subjects: 418
Study 35898486 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily finger gymnastics; exercise 2-3 times per day, ibuprofen sustained-release capsules if excessive pain occurs.
Number of subjects: 60
Study 35898486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 60
Study 32727157 — intervention group
Group type: EXPERIMENTAL
Intervention: Donkey Milk-Based Fortifiers (D-HMF)
Number of subjects: 54
Study 32727157 — intervention group
Group type: COMPARATOR
Intervention: Bovine Milk-Based Fortifiers (B-HMF)
Number of subjects: 54
Study 36467884 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibratable patient-specific instrumentation (PSI)
Number of subjects: 37
Study 36467884 — intervention group
Group type: COMPARATOR
Intervention: Conventional operation (CO)
Number of subjects: 37
Study 33332191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical maintenance Bacillus Calmette‐Guerin (mBCG)
Number of subjects: 50
Study 33332191 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy (RC)
Number of subjects: 50
Study 33332191 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 50
Study 33332191 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL)
Number of subjects: 50
Study 36273682 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus a newly initiated oral antidepressant (ESK+AD)
Number of subjects: 560
Study 36273682 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray plus oral antidepressant (AD+PBO)
Number of subjects: 560
Study 33899195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) recovery after exercise
Number of subjects: 20
Study 33899195 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery after exercise
Number of subjects: 20
Study 32454841 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (story reading and nature exposure for 20 minutes each week for three weeks)
Number of subjects: 200
Study 32454841 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (received intervention instructions three weeks later)
Number of subjects: 200
Study 32454841 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 200
Study 35410736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartoon watching
Number of subjects: 56
Study 35410736 — intervention group
Group type: COMPARATOR
Intervention: Bubble-blowing
Number of subjects: 56
Study 33894690 — intervention group
Group type: EXPERIMENTAL
Intervention: FIFA11+kid (n = 28, 5 times per week)
Number of subjects: 55
Study 33894690 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 27)
Number of subjects: 55
Study 32747216 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV-bOPV-bOPV
Number of subjects: 648
Study 32747216 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-bOPV
Number of subjects: 648
Study 32747216 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-sIPV
Number of subjects: 648
Study 34416778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen enema
Number of subjects: 0
Study 34416778 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen suppository
Number of subjects: 0
Study 34416778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ibuprofen enema and suppository
Number of subjects: 0
Study 33375952 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP) 0.02 mg/kg IM
Number of subjects: 12
Study 33375952 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release buprenorphine (BSR) 0.2 mg/kg SC
Number of subjects: 12
Study 35747181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose measles vaccination (MV) at 4 and 9 months
Number of subjects: 6598
Study 35747181 — intervention group
Group type: COMPARATOR
Intervention: 1-dose measles vaccination (MV) at 9 months
Number of subjects: 6598
Study 35747181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose measles vaccination (MV) with no C-OPV
Number of subjects: 6598
Study 35747181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose measles vaccination (MV) with C-OPV
Number of subjects: 6598
Study 35747181 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose measles vaccination (MV) at 4 months with maternal measles antibodies (MatAb)
Number of subjects: 6598
Study 32966722 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zinc sulfate for 14 days
Number of subjects: 4500
Study 32966722 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zinc sulfate for 14 days
Number of subjects: 4500
Study 32966722 — intervention group
Group type: COMPARATOR
Intervention: 20 mg zinc sulfate for 14 days
Number of subjects: 4500
Study 36097716 — intervention group
Group type: EXPERIMENTAL
Intervention: High controlling language
Number of subjects: 0
Study 36097716 — intervention group
Group type: EXPERIMENTAL
Intervention: High fear appeals
Number of subjects: 0
Study 36097716 — intervention group
Group type: EXPERIMENTAL
Intervention: High disgust appeals
Number of subjects: 0